Please login to the form below
ribociclib
This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.
Lilly boosted by survival data for key growth drug Verzenio
However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder.
Latest news
-
Novartis raises 2019 guidance as new products gather speed
from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from
-
NICE says no to Novartis’ Kisqali combo in breast cancer
Draft guidance from the cost-effectiveness watchdog has concluded CDK 4/6 inhibitor Kisqali (ribociclib) plus fulvestrant should not be offered routinely on the NHS in England for patients with hormone ... More data may address the uncertainties in the
-
NICE nod for Lilly’s breast cancer drug Verzenio via CDF
The approval sets Verzenio up as a second-line option after other drugs in the CDK 4/6 inhibitor class – including Verzenio itself as well as Novartis’ Kisqali (ribociclib) and ... $6bn product at peak by EvaluatePharma – as well as Novartis’
-
NICE gives Lilly’s Verzenios chance to compete with rivals
Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in ... Abemaciclib has been shown to be just as
More from news
Approximately 4 fully matching, plus 30 partially matching documents found.
Latest appointments
-
Ipsen boosts specialty care and R&D leadership teams
East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
VCCP Health
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
